SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Munch-a-Biotech Today
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: RWReeves who wrote (369)5/11/1999 4:12:00 PM
From: Biomaven  Read Replies (1) of 3158
 
Sounds to me like they will return only cash to the shareholders. The HQL portfolio at year end (latest I could find) was actually pretty reasonable, with SEPR the biggest holding. About 20% is in private companies, most of which I haven't heard of. Don't know how they value them, but given the state of the IPO market for biotechs they can't be worth much (except maybe Tularik?).

Actually HQL could be a pretty reasonable short-term play based solely on the 25% discount shrinking.

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News